For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Dual Action Pneumatic Compression Device | ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks. Dual Action Pneumatic Compression Device: Dual action pneumatic compression device used to treat chronic VLUs. | 0 | None | 1 | 26 | 17 | 26 | View |
| Multi-layer Bandaging | PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks. Multi-Layer Bandaging: Multi-layer bandaging used to treated chronic VLUs | 0 | None | 2 | 30 | 12 | 30 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Pain/Discomfort | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Ulcer | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Blister | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Other | SYSTEMATIC_ASSESSMENT | General disorders | None | View |